E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Marine Compounds in Neurodegenerative Diseases"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 31 May 2018

Special Issue Editors

Guest Editor
Prof. Dr. Patrizia Russo

IRCCS San Raffaele Pisana, Area of Clinical and Molecular Epidemiology, 00166 Rome, Italy
E-Mail
Interests: Applied biology,nicotinic receptor in cancer, COPD, addiction, Alzheimer, systems medicine
Guest Editor
Prof. Dr. Massimo Fini

Scientific Direction, IRCCS San Raffaele Pisana, Rome, Italy
E-Mail
Phone: 06-6613-0405
Interests: Systems medicine, aging, frailty, rehabilitation, cardiovascular

Special Issue Information

Dear Colleagues,

Aging-associated neurodegenerative diseases (NDs), such as Alzheimer's disease (AD) and AD-like pathologies, such as changes in Aβ40/42 ratios, tau hyperphosphorylation and endosome abnormalities, Parkinson's disease (PD), frontotemporal degeneration (FTD) and amyotrophic lateral sclerosis (ALS), among others, are unremittingly progressive and fatal neurological diseases. NDs are characterized by irreversible loss of neurons/cholinergic or dopaminergic receptors functionality that results in apoptosis and, in turn, in severe atrophy of the affected patient brain regions. Pathogenesis of NDs are complex and the underlying mechanisms are yet to be fully explored.

Neurodegeneration is associated to neuroinflammation a dynamic biological response characterized by the recruitment of innate and adaptive immune system cells in the site of tissue damage. Activation of resident microglia and infiltrating immune cells may contribute to the disease process itself.

This Special Issue “Marine Compounds in Neurodegenerative Diseases” of Marine Drugs will cover the whole scope of agents targeting the mechanisms underlying NDs. This Special issue is focused on (but not limited to) compounds with relevant biological activities; however, preclinical drugs are also investigated.

Prof. Dr. Patrizia Russo
Prof. Dr. Massimo Fini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurodegenerative diseases
  • neuroinflammation
  • marine compounds
  • cell death
  • cell survival
  • drug resistance
  • necrosis

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Review

Open AccessReview Application of Chitosan, Chitooligosaccharide, and Their Derivatives in the Treatment of Alzheimer’s Disease
Mar. Drugs 2017, 15(11), 322; doi:10.3390/md15110322
Received: 23 September 2017 / Revised: 12 October 2017 / Accepted: 13 October 2017 / Published: 7 November 2017
PDF Full-text (421 KB) | HTML Full-text | XML Full-text
Abstract
Classic hypotheses of Alzheimer’s disease (AD) include cholinergic neuron death, acetylcholine (ACh) deficiency, metal ion dynamic equilibrium disorder, and deposition of amyloid and tau. Increased evidence suggests neuroinflammation and oxidative stress may cause AD. However, none of these factors induces AD independently, but
[...] Read more.
Classic hypotheses of Alzheimer’s disease (AD) include cholinergic neuron death, acetylcholine (ACh) deficiency, metal ion dynamic equilibrium disorder, and deposition of amyloid and tau. Increased evidence suggests neuroinflammation and oxidative stress may cause AD. However, none of these factors induces AD independently, but they are all associated with the formation of Aβ and tau proteins. Current clinical treatments based on ACh deficiency can only temporarily relieve symptoms, accompanied with many side-effects. Hence, searching for natural neuroprotective agents, which can significantly improve the major symptoms and reverse disease progress, have received great attention. Currently, several bioactive marine products have shown neuroprotective activities, immunomodulatory and anti-inflammatory effects with low toxicity and mild side effects in laboratory studies. Recently, chitosan (CTS), chitooligosaccharide (COS) and their derivatives from exoskeletons of crustaceans and cell walls of fungi have shown neuroprotective and antioxidative effects, matrix metalloproteinase inhibition, anti-HIV and anti-inflammatory properties. With regards to the hypotheses of AD, the neuroprotective effect of CTS, COS, and their derivatives on AD-like changes in several models have been reported. CTS and COS exert beneficial effects on cognitive impairments via inhibiting oxidative stress and neuroinflammation. They are also a new type of non-toxic β-secretase and AChE inhibitor. As neuroprotective agents, they could reduce the cell membrane damage caused by copper ions and decrease the content of reactive oxygen species. This review will focus on their anti-neuroinflammation, antioxidants and their inhibition of β-amyloid, acetylcholinesterase and copper ions adsorption. Finally, the limitations and future work will be discussed. Full article
(This article belongs to the Special Issue Marine Compounds in Neurodegenerative Diseases)
Figures

Figure 1

Back to Top